孕激素及孕激素受体与卵巢癌关系的研究进展  

Research Progress in the Relationship between Progesterone,Progesterone Receptors and Ovarian Cancer

作　　者：骆丹 郑洪[1] LUO Dan;ZHENG Hong(Department of Pathology,Affiliated Hospital of Zunyi Medical College, Zunyi 563000, Chin)

机构地区：[1]遵义医学院附属医院病理教研室,贵州遵义563000

出　　处：《医学综述》2018年第9期1709-1713,共5页Medical Recapitulate

基　　金：贵州省科技厅联合基金(黔科合LH字[2015]7455号)

摘　　要：卵巢癌是致死率最高的妇科生殖系统恶性肿瘤,被称作"沉默杀手"。卵巢癌病因、起源和发病机制至今尚不明确且有争议。孕激素在上皮性卵巢癌发生中的作用仍是研究的重点课题,相当多的流行病学资料表明孕激素在卵巢癌变过程中发挥保护卵巢的作用,口服避孕药和妊娠能够降低卵巢癌发生风险得到一致认可。孕激素通过基因组和非基因组作用介导发挥生理学效应,非基因组的作用越来越受到重视。研究认为孕激素受体阳性卵巢癌患者预后较好,孕激素受体B亚型可以独立地作为卵巢癌的预后因子。Ovarian cancer is the most lethal gynecologic malignancy,known as ＂ silent killer＂. Despite considerable research,the etiology,origin and pathogenesis of ovarian cancer have not been clarified and remain elusive. The role of progesterone in the development of epithelial ovarian cancer is still the focus of research,a considerable body of epidemiological data suggests that progesterone plays a protective role against ovarian carcinogenesis. Progesterone plays a physiological role through genomic and non-genomic effects,and the latter is getting more and more attention. It is considered that progesterone receptor positive ovarian cancer patients have better prognosis. Progesterone receptor B subtype can be used as a prognostic factor of ovarian cancer independently.

关 键 词：卵巢癌 孕激素 非基因组 孕激素受体亚型 预后 

分 类 号：R737.31[医药卫生—肿瘤]